{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:07:41Z","timestamp":1788314861595,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA023766"],"award-info":[{"award-number":["P01 CA023766"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA55349"],"award-info":[{"award-number":["R01 CA55349"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R35 CA241894"],"award-info":[{"award-number":["R35 CA241894"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI118224"],"award-info":[{"award-number":["R01 AI118224"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tudor Fund (DAS), Lymphoma Fund (DAS), Commonwealth Foundation and MSK Center for Experimental Therapeutics"},{"name":"See TAN entry"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Chem Biol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1038\/s41589-021-00932-1","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T12:02:36Z","timestamp":1640865756000},"page":"216-225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Engineering CAR-T cells to activate small-molecule drugs in situ"],"prefix":"10.1038","volume":"18","author":[{"given":"Thomas J.","family":"Gardner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4507-046X","authenticated-orcid":false,"given":"J. Peter","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9290-4223","authenticated-orcid":false,"given":"Christopher M.","family":"Bourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinali","family":"Wijewarnasuriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0320-7600","authenticated-orcid":false,"given":"Nihar","family":"Kinarivala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keifer G.","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Broderick C.","family":"Corless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-1502","authenticated-orcid":false,"given":"Megan M.","family":"Dacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7770-7405","authenticated-orcid":false,"given":"Aaron Y.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8621-8603","authenticated-orcid":false,"given":"Kha M.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3364-5388","authenticated-orcid":false,"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7956-9659","authenticated-orcid":false,"given":"Derek S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4160-923X","authenticated-orcid":false,"given":"David A.","family":"Scheinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,30]]},"reference":[{"key":"932_CR1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1053\/j.seminoncol.2015.05.005","volume":"42","author":"SA Feldman","year":"2015","unstructured":"Feldman, S. A., Assadipour, Y., Kriley, I., Goff, S. L. & Rosenberg, S. A. Adoptive cell therapy\u2014tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors. Semin. Oncol. 42, 626\u2013639 (2015).","journal-title":"Semin. Oncol."},{"key":"932_CR2","doi-asserted-by":"publisher","first-page":"101437","DOI":"10.1016\/j.smim.2020.101437","volume":"49","author":"E Leon","year":"2020","unstructured":"Leon, E., Ranganathan, R. & Savoldo, B. Adoptive T cell therapy: boosting the immune system to fight cancer. Semin. Immunol. 49, 101437 (2020).","journal-title":"Semin. Immunol."},{"key":"932_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., Rivi\u00e8re, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423\u2013431 (2017).","journal-title":"Nature"},{"key":"932_CR4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/MOH.0000000000000614","volume":"27","author":"O Beyar-Katz","year":"2020","unstructured":"Beyar-Katz, O. & Gill, S. Advances in chimeric antigen receptor T cells. Curr. Opin. Hematol. 27, 368\u2013377 (2020).","journal-title":"Curr. Opin. Hematol."},{"key":"932_CR5","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"932_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hon.2591","volume":"37","author":"D Sermer","year":"2019","unstructured":"Sermer, D. & Brentjens, R. CAR T-cell therapy: full speed ahead. Hematol. Oncol. 37, 95\u2013100 (2019).","journal-title":"Hematol. Oncol."},{"key":"932_CR7","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282\u20131295 (2015).","journal-title":"Cancer Discov."},{"key":"932_CR8","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"932_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"932_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson, K. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31, 311\u2013325 (2017).","journal-title":"Cancer Cell"},{"key":"932_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","volume":"11","author":"D Kasakovski","year":"2018","unstructured":"Kasakovski, D., Xu, L. & Li, Y. T cell senescence and CAR-T cell exhaustion in hematological malignancies. J. Hematol. Oncol. 11, 91 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"932_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy: assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"932_CR13","doi-asserted-by":"publisher","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","volume":"359","author":"CE Dunbar","year":"2018","unstructured":"Dunbar, C. E. et al. Gene therapy comes of age. Science 359, eaan4672 (2018).","journal-title":"Science"},{"key":"932_CR14","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724\u2013740 (2017).","journal-title":"Cell"},{"key":"932_CR15","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 36, 847\u2013856 (2018).","journal-title":"Nat. Biotechnol."},{"key":"932_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku, O. O., Purdon, T. J., Koneru, M., Spriggs, D. & Brentjens, R. J. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci. Rep. 7, 10541 (2017).","journal-title":"Sci. Rep."},{"key":"932_CR17","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi, M. P. et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 23, 2130\u20132141 (2018).","journal-title":"Cell Rep."},{"key":"932_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.cell.2016.08.032","volume":"167","author":"M Boice","year":"2016","unstructured":"Boice, M. et al. Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells. Cell 167, 405\u2013418 (2016).","journal-title":"Cell"},{"key":"932_CR19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","volume":"35","author":"NF Kuhn","year":"2019","unstructured":"Kuhn, N. F. et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 35, 473\u2013488 (2019).","journal-title":"Cancer Cell"},{"key":"932_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 34, 45\u201355 (2019).","journal-title":"Blood Rev."},{"key":"932_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","volume":"69","author":"JM Lambert","year":"2018","unstructured":"Lambert, J. M. & Berkenblit, A. Antibody-drug conjugates for cancer treatment. Annu. Rev. Med. 69, 191\u2013207 (2018).","journal-title":"Annu. Rev. Med."},{"key":"932_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2017.1247802","volume":"17","author":"SK Sharma","year":"2017","unstructured":"Sharma, S. K. & Bagshawe, K. D. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination. Expert Opin. Biol. Ther. 17, 1\u201313 (2017).","journal-title":"Expert Opin. Biol. Ther."},{"key":"932_CR23","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/sj.cgt.7700634","volume":"10","author":"J Nemunaitis","year":"2003","unstructured":"Nemunaitis, J. et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 10, 737\u2013744 (2003).","journal-title":"Cancer Gene Ther."},{"key":"932_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1432-1033.1985.tb08860.x","volume":"148","author":"RF Sherwood","year":"1985","unstructured":"Sherwood, R. F., Melton, R. G., Alwan, S. M. & Hughes, P. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur. J. Biochem. 148, 447\u2013453 (1985).","journal-title":"Eur. J. Biochem."},{"key":"932_CR25","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(63)92051-8","volume":"1","author":"PC Fleming","year":"1963","unstructured":"Fleming, P. C., Goldner, M. & Glass, D. G. Observations on the nature, distribution, and significance of cephalosporinase. Lancet 1, 1399\u20131401 (1963).","journal-title":"Lancet"},{"key":"932_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/0014-4894(70)90121-9","volume":"28","author":"JJ Jaffe","year":"1970","unstructured":"Jaffe, J. J., McCormack, J. J. & Meymerian, E. Trypanocidal properties of 5\u2032-O-sulfamoyladenosine, a close structural analog of nucleocidin. Exp. Parasitol. 28, 535\u2013543 (1970).","journal-title":"Exp. Parasitol."},{"key":"932_CR27","first-page":"49","volume":"25","author":"S Rengaraju","year":"1986","unstructured":"Rengaraju, S. et al. 5\u2032-O-Sulfamoyladenosine (defluoronucleocidin) from a Streptomyces. Meiji Seika Kenkyu Nenpo 25, 49\u201355 (1986).","journal-title":"Meiji Seika Kenkyu Nenpo"},{"key":"932_CR28","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/sj.bjc.6600517","volume":"87","author":"RJ Francis","year":"2002","unstructured":"Francis, R. J. et al. A Phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br. J. Cancer 87, 600\u2013607 (2002).","journal-title":"Br. J. Cancer"},{"key":"932_CR29","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1021\/jm00026a013","volume":"38","author":"CJ Springer","year":"1995","unstructured":"Springer, C. J. et al. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J. Med. Chem. 38, 5051\u20135065 (1995).","journal-title":"J. Med. Chem."},{"key":"932_CR30","doi-asserted-by":"publisher","first-page":"7119","DOI":"10.1016\/j.bmc.2015.09.050","volume":"23","author":"B Yoo","year":"2015","unstructured":"Yoo, B. et al. Ultrasmall dual-modality silica nanoparticle drug conjugates: design, synthesis, and characterization. Bioorg. Med. Chem. 23, 7119\u20137130 (2015).","journal-title":"Bioorg. Med. Chem."},{"key":"932_CR31","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1158\/1535-7163.MCT-05-0189","volume":"4","author":"FA Harding","year":"2005","unstructured":"Harding, F. A. et al. A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol. Cancer Ther. 4, 1791\u20131800 (2005).","journal-title":"Mol. Cancer Ther."},{"key":"932_CR32","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/nbt1297-1373","volume":"15","author":"R Marais","year":"1997","unstructured":"Marais, R. et al. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat. Biotechnol. 15, 1373\u20131377 (1997).","journal-title":"Nat. Biotechnol."},{"key":"932_CR33","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","volume":"13","author":"RJ Brentjens","year":"2007","unstructured":"Brentjens, R. J. et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13, 5426\u20135435 (2007).","journal-title":"Clin. Cancer Res."},{"key":"932_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02460-2","volume":"7","author":"Z Liu","year":"2017","unstructured":"Liu, Z. et al. Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. Sci. Rep. 7, 2193 (2017).","journal-title":"Sci. Rep."},{"key":"932_CR35","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1016\/S0021-9258(18)99594-3","volume":"242","author":"CC Levy","year":"1967","unstructured":"Levy, C. C. & Goldman, P. The enzymatic hydrolysis of methotrexate and folic acid. J. Biol. Chem. 242, 2933\u20132938 (1967).","journal-title":"J. Biol. Chem."},{"key":"932_CR36","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1128\/AAC.43.7.1743","volume":"43","author":"A Bulychev","year":"1999","unstructured":"Bulychev, A. & Mobashery, S. Class C beta-lactamases operate at the diffusion limit for turnover of their preferred cephalosporin substrates. Antimicrob. Agents Chemother. 43, 1743\u20131746 (1999).","journal-title":"Antimicrob. Agents Chemother."},{"key":"932_CR37","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nm.1930","volume":"15","author":"EB Santos","year":"2009","unstructured":"Santos, E. B. et al. Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat. Med. 15, 338\u2013344 (2009).","journal-title":"Nat. Med."},{"key":"932_CR38","doi-asserted-by":"publisher","first-page":"329121","DOI":"10.1155\/2013\/329121","volume":"2013","author":"N Gurung","year":"2013","unstructured":"Gurung, N., Ray, S., Bose, S. & Rai, V. A broader view: microbial enzymes and their relevance in industries, medicine, and beyond. BioMed. Res. Int. 2013, 329121 (2013).","journal-title":"BioMed. Res. Int."},{"key":"932_CR39","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1038\/sj.bjc.6601888","volume":"90","author":"A Mayer","year":"2004","unstructured":"Mayer, A. et al. Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br. J. Cancer 90, 2402\u20132410 (2004).","journal-title":"Br. J. Cancer"},{"key":"932_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0280-y","volume":"10","author":"S Liu","year":"2020","unstructured":"Liu, S. et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 10, 15 (2020).","journal-title":"Blood Cancer J."},{"key":"932_CR41","unstructured":"Bagshawe, K. D. & Sharma, S. K. Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT. in Proc. International Conference on New Trends in Clinical and Experimental Immunosuppression, Geneva (1996)."},{"key":"932_CR42","doi-asserted-by":"publisher","first-page":"15804","DOI":"10.1074\/jbc.272.25.15804","volume":"272","author":"GK Smith","year":"1997","unstructured":"Smith, G. K. et al. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. J. Biol. Chem. 272, 15804\u201315816 (1997).","journal-title":"J. Biol. Chem."},{"key":"932_CR43","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/sj.bjc.6600519","volume":"87","author":"D Oosterhoff","year":"2002","unstructured":"Oosterhoff, D. et al. Secreted and tumour targeted human carboxylesterase for activation of irinotecan. Br. J. Cancer 87, 659\u2013664 (2002).","journal-title":"Br. J. Cancer"},{"key":"932_CR44","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/sj.cgt.7700999","volume":"14","author":"KC Chen","year":"2007","unstructured":"Chen, K. C. et al. Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes. Cancer Gene Ther. 14, 187\u2013200 (2007).","journal-title":"Cancer Gene Ther."},{"key":"932_CR45","doi-asserted-by":"publisher","unstructured":"Peraro, L. et al. Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection Mol. Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2021.06.022 (2021).","DOI":"10.1016\/j.ymthe.2021.06.022"},{"key":"932_CR46","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"932_CR47","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.3390\/cancers12082175","volume":"12","author":"TJ Gardner","year":"2020","unstructured":"Gardner, T. J. et al. Targeted cellular micropharmacies: cells engineered for localized drug delivery. Cancers 12, 2175 (2020).","journal-title":"Cancers"},{"key":"932_CR48","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1182\/blood-2007-02-072843","volume":"110","author":"C Quintarelli","year":"2007","unstructured":"Quintarelli, C. et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 110, 2793\u20132802 (2007).","journal-title":"Blood"},{"key":"932_CR49","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nbt.4090","volume":"36","author":"K Garber","year":"2018","unstructured":"Garber, K. Driving T-cell immunotherapy to solid tumors. Nat. Biotechnol. 36, 215\u2013219 (2018).","journal-title":"Nat. Biotechnol."},{"key":"932_CR50","doi-asserted-by":"publisher","first-page":"6733","DOI":"10.1073\/pnas.92.15.6733","volume":"92","author":"I Riviere","year":"1995","unstructured":"Riviere, I., Brose, K. & Mulligan, R. C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl Acad. Sci. USA 92, 6733\u20136737 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"932_CR51","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783\u2013784 (2014).","journal-title":"Nat. Methods"}],"container-title":["Nature Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41589-021-00932-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-021-00932-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-021-00932-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T03:14:19Z","timestamp":1676085259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41589-021-00932-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,30]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1038\/s41589-021-00932-1","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741385871.793591526","asserted-by":"object"}]},"ISSN":["1552-4450","1552-4469"],"issn-type":[{"value":"1552-4450","type":"print"},{"value":"1552-4469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,30]]},"assertion":[{"value":"23 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A.S., D.S.T. and R.J.B. are consultants for, have equity in and have sponsored research agreements with CoImmune, which has licensed technology described in this paper from MSK. D.A.S. has equity in or is a consultant for: Actinium Pharmaceuticals, Arvinas, Eureka Therapeutics, Iovance Biotherapeutics, OncoPep, Pfizer, Repretoire and Sellas. D.S.T. has been a consultant and\/or paid speaker for Eli Lilly, Elsevier, Emerson Collective, Merck, National Institutes of Health, Venenum Biodesign, the Research Center for Molecular Medicine of the Austrian Academy of Sciences and the Institute for Research in Biomedicine, Barcelona. R.J.B. is a cofounder and receives royalties from Juno Therapeutics\/Celgene. MSK has filed for patent protection behalf of T.J.G., J.P.L., D.S.T. and D.A.S. for inventions described in this paper. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}